Dokumente
Suchschritt : FT=glucosamine AND FT=osteoarthritis
» Fenster schließen »

2/71 von 416 DIMDI: MEDLINE (ME60) © NLM

ND: | ME16483910
PMID: | 16483910
CED: | 20060217
DCO: | 20060718
Autoren: | McAlindon TE
Titel: | Nutraceuticals: do they work and when should we use them?
Quelle: | Best practice & research. Clinical rheumatology; VOL: 20 (1); p. 99-115 /200602/
PM: | Print
SU: | IM
Sprache: | English
CY: | England
JID: | 101121149
ISSN: | 1521-6942
Institution: | Tufts-New England Medical Center, Boston, MA 02111, USA. tmcalindon@tufts-nemc.org
DT: | Journal Article; Review
RN: | 120
Schlagwörter
CT: | DIETARY SUPPLEMENTS/*; HUMANS; NUTRITIONAL SUPPORT/*methods; OSTEOARTHRITIS/*diet therapy; TREATMENT OUTCOME
CTG: | NAHRUNGSERGÄNZUNGSMITTEL/*; MENSCH; NAHRUNGSZUFUHR/*Methoden; OSTEOARTHROSE/*Diättherapie; BEHANDLUNGSERGEBNIS
AB: | There are numerous biological mechanisms by which nutritional factors might be expected to exert favorable influences on pathophysiological processes in osteoarthritis. Such processes include oxidative damage, cartilage matrix degradation and repair, and chondrocyte function and responses in adjacent bone. Micronutrients for which preliminary evidence of benefit exists include vitamin C and vitamin D. In addition, numerous nutraceuticals that may influence osteoarthritis pathophysiology--including glucosamine, chondroitin, S-adenosylmethionine, ginger and avocado/soybean unsaponifiables--have been tested in clinical trials. These products are safe and well tolerated, but interpretation of the collective results is hampered by heterogeneity of the studies, inconsistent results, and the conundrum of how to reconcile an apparent structural benefit with absence or modest effect on symptoms.

» Volltext »
» Fenster schließen »